PHARMACEUTICAL FORMULATION FOR TREATING ALLERGIC R HINITIS AND PREPARATION METHOD THEREOF FIELD OF THE INVENTION [0001]The invention relates to the field of traditional Chinese medicine (TCM), and more particularly to a pharmaceutical formulation for treatment of allergic rhinitis and a method for preparing the same. BACKGROUND OF THE INVENTION [0002]Allergic rhinitis, also known as hypersensitivity, is an allergic disease of nasal mucosa resulting from the sensitivity of the body to allergens. Allergic rhinitis is totally different from rhinitis and sinusitis in the nature of disease, with an incidence rate of between 5% and 50%, and seriously endangers the human health. Western medicine treats allergic rhinitis by avoiding contact with allergens, use of drugs, immunization, or desensitization, all of which are expensive, difficult for popularization, and poor in therapeutic effect. Traditional Chinese medicine treats allergic rhinitis by using rhinitis tablets or Xinqin granules (a TCM formulation). The Xinqin granules are capable of invigorating Qi (a TCM concept) for consolidating superficial resistance, and expelling wind and promoting the restoration of consciousness. The Xinqin granules are mainly used for treatment of diseases resulting from lung Qi deficiency and attack by pathogenic wind, which aims at expelling wind. The rhinitis tablets are capable of invigorating Qi, expelling wind, and promoting the restoration of consciousness. The rhinitis tablets are mainly used for treatment of diseases such as physically weak spontaneous sweating, recurrent colds, nasal congestion, and runny nose, which 1 RECEIVED TIME 4. NOV. 142 aims at invigorating Qi and relaxing. Some rhinitis tablets are capable of clearing heat and detoxication, expelling wind, and promoting the restoration of consciousness, which are mainly used for treatment of wind-heat diseases by clearing heat and detoxication. Additionally, another ten kinds of Chinese patent drugs are also reported for treatment of nasal diseases on the basis of clearing heat and detoxication, but they are not suitable for treatment of allergic rhinitis. [0003] Based on the dialectical analysis of allergic rhinitis (Correlation of type of syndrome of allergic rhinitis and clinical features, Journal of Traditional Chinese Medicine, Vol. 45, No. 5, May, 2004), 256 patients suffering from allergic rhinitis were conducted with acidophil detection and serum globulin detection from nasal secreta. The results showed that allergic rhinitis-attacked patients suffers from lung Qi deficiency and spleen Qi deficiency, accounting for 48.4% and 28.2%, respectively. That is to say, 76.6% of the allergic rhinitis-attacked patients suffer from lung or spleen Qi deficiency, so the treatment should place emphasis on strengthening spleen and tonifying lung, warming and nourishing Qi and blood for improving the constitutive character of patients, and meanwhile aim at expelling wind to relieve the nasal syndromes, whereby curing the disease in essence. Traditional western and Chinese treatments do not specifically treat allergic rhinitis, and thus the treatment effect is not satisfied. SUMMARY OF THE INVENTION [0004] In view of the above-described problems, it is one objective of the invention to provide a pharmaceutical formulation for treatment of allergic rhinitis and a preparation method thereof. [0005] The objective of the invention is achieved according to the following technical schemes. 2 RECEIVED TIME 4. NOV. 11:42 [0006] A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, between 5 and 20; Radix saposhnikoviae, between 5 and 15; Herba ephedrae, between 2 and 6; F/os Magnoliae, between 2 and 10; Angelica dahurica, between 2 and 10; Rhizorna Atractylodis Macrocephalae, between 5 and 15; Poriacocos, between 2 and 10; Bupleururn, between 2 and 10; Radix Ange/icae Sinensis, between 2 and 10; Cortex Moutan Radicis, between 2 and 10 Fructus Schisandrae Chinensis, between 2 and 10; Fructus Mumne, between 2 and 10; Radix Scutellariae, between 2 and 10; and Glycyrrhiza uralensis Fisch, between 2 and 10. [0007] The invention further provides a method for preparing the pharmaceutical formulation, comprising the following steps: [0008] a) breaking the Flos Magnoliae, Cortex Moutan Radicis, Radix saposhnikoviae, Radix Angelicae Sinensis, and Rhizorna Atracty/odis Macrocephalae into pieces, adding water to the pieces, allowing to stand for 6 hours, filtering, extracting volatile oil, and collecting an aqueous filtrate and a herb residue; [0009] b) encaging the volatile oil by using P-cyclodextrin to yield a clathrate compound, a ratio of the volatile oil to the P-cyclodextrin being 1 mL: 8 g; [0010] c) mixing the Poriacocos, Fructus Mume, Herba ephedrae, Radix Scute//ariae, and Glycyrrhiza uralensis Fisch with the herb residue collected in step a), adding water to the herb residue to yield a mixture, decocting the mixture twice each for 1.5 hours, and combining the mixture with the aqueous filtrate obtained in step a) to yield a first concentrate; [0011] d) purifying the Angelica dahurica, Fructus Schisandrae Chinensis, Astraga/us membranaceus, and Bupleurum using a 70 % (v/v) alcohol solution 3 RECEIVED TIME 4. NOV. 17:42 three times each for 2 hours, combining the alcohol solution and removing alcohol to yield a second concentrate, mixing the first concentrate and the second concentrate to yield a clear paste or vacuum drying the clear paste to yield a powder; [0012]e) adding the clathrate compound and a pharmaceutical powder to the clear paste or the powder, or adding the clathrate compound and a pharmaceutical additive to the clear paste or the powder. [0013] In step e), the method further comprises drying, polishing, and packaging the pharmaceutical formulation at less than 500C to yield a concentrated pill, tablet, granule, or capsule. [0014] The first concentrate obtained in step c) has a relative density of between 1.15 and 1.20 at 500C, and the clear paste obtained in step d) has a relative density of 1.35 at 50*C. [0015] The pharmaceutical powder comprises between 20 and 35 wt. % of each of the ingredients. [0016] The pharmaceutical additive comprises a medicinal starch and microcrystalline cellulose. [0017] Advantages of the invention are summarized as follows: [0018]1. The pharmaceutical formulation comprises ingredients capable of anti-inflammation, anti-allergy, and improving the body immunity and thus the pharmaceutical formulation inhibits the development of hypersensitivity of allergic rhinitis by the bidirectional regulation of the immunity. The formulation also has effect for fighting against concurrent allergic bronchial complications, with extra effects such as analgesia, antipruritic, antibacteria and antivirus. The formulation is safe and reliable, has low side effect, sustained efficacy, stability, and low 4 RECEIVED TIME 4. NOV. 11:42 recurrence rate. [0019]2. The pharmaceutical formulation is prepared using advanced technology and has high active ingredients, with low volume, small dosage, and low side effect. The efficacy is high, immediate, and long-acting. The packaging, transportation, storage, taking, and administration of the formulation are convenient. [0020]3. The pharmaceutical formulation can be prepared in dosage forms such as concentrated honey pills, water-honeyed pills, water-bound pills, tablets, granules, and capsules, which can meet various requirements. [0021] 4. The pharmaceutical formulation places emphasis on strengthening spleen and tonifying lung, warming and nourishing Qi and blood for improving the constitutive character of patients, and meanwhile aim at expelling wind to relieve the nasal syndromes, whereby treating allergic rhinitis in essence. DETAILED DESCRIPTION OF THE EMBODIMENTS [0022] Detailed description of the invention will be given below in conjunction with examples. [0023] A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, between 5 and 20; Radix saposhnikoviae, between 5 and 15; Herba ephedrae, between 2 and 6; Flos Magnoliae, between 2 and 10; Angelica dahurica, between 2 and 10; Rhizoma Atractylodis Macrocephalae, between 5 and 15; Poriacocos, between 2 and 10; Bupleurum, between 2 and 10; Radix Ange/icae Sinensis, between 2 and 10; Cortex Moutan Radicis, between 2 and 10; Fructus Schisandrae Chinensis, between 2 and 10; Fructus Mume, between 2 5 RECEIVED TIME 4, NOV. 17:42 and 10; Radix Scutel/ariae, between 2 and 10; and Glycyrrhiza uralensis Fisch, between 2 and 10. Example 1 [0024] A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, 50 g; Radix saposhnikoviae, 50 g; Herba ephedrae, 20 g; Flos Magnoliae, 20 g; Angelica dahurica, 20 g; Rhizoma Atractylodis Macrocephalae, 50 g; Poriacocos, 20 g; Bupleurum, 20 g; Radix Angelicae Sinensis, 20 g; Cortex Moutan Radicis, 20 g; Fructus Schisandrae Chinensis, 20 g; Fructus Mume, 20 g' Radix Scutellariae, 20 g; and Glycyrrhiza uralensis Fisch, 20 g. [0025] A method for preparing the pharmaceutical formulation, comprises the following steps: [0026] a) breaking the Flos Magnoliae, Cortex Moutan Radicis, Radix saposhnikoviae, Radix Angelicae Sinensis, and Rhizoma Atractylodis Macrocephalae into pieces, adding water to the pieces, allowing to stand for 6 hours, filtering, extracting volatile oil, and collecting an aqueous filtrate and a herb residue; [0027] b) encaging the volatile oil by using P-cyclodextrin to yield a clathrate compound, a ratio of the volatile oil to the P-cyclodextrin being 1 mL: 8 g; [0028] c) mixing the Poriacocos, Fructus Mume, Herba ephedrae, Radix Scutelariae, and Glycyrrhiza uralensis Fisch with the herb residue collected in step a), adding water to the herb residue to yield a mixture, decocting the mixture twice each for 1.5 hours, and combining the mixture with the aqueous filtrate obtained in step a) to yield a first concentrate, the 6 RECEIVED TIME 4, NOV. 17:42 first concentrate having a relative density of 1.15 at 50*C; [0029] d) purifying the Angelica dahurica, Fructus Schisandrae Chinensis, Astragalus membranaceus, and Bupleurum using a 70 % (v/v) alcohol solution three times each for 2 hours, combining the alcohol solution and removing alcohol to yield a second concentrate, mixing the first concentrate and the second concentrate to yield a clear paste, the clear paste having a relative density of 1.35 at 50"C; [0030] e) adding the clathrate compound and a medical starch to the clear paste or the powder, drying, polishing, and packaging the pharmaceutical formulation at less than 500C to yield a concentrated water-bound pill. Example 2 [0031 ]A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, 200 g; Radix saposhnikoviae, 150 g; Herba ephedrae, 60 g; Flos Magnoliae, 100 g; Angelica dahurica, 100 g; Rhizoma Atractylodis Macrocephalae, 150 g; Poriacocos, 100 g; Bupleurum, 100 g; Radix Angelicae Sinensis, 100 g; Cortex Moutan Radicis, 100 g; Fructus Schisandrae Chinensis, 100 g; Fructus Mume, 100 g; Radix Scutellariae, 100 g; and Glycyrrhiza uralensis Fisch, 100 g. [0032]A method for preparing the pharmaceutical formulation, comprises the following steps: [0033] First, dividing the above ingredients into two parts. The first part is used for the extraction according to the following steps a)-d), and the second part is ground into a pharmaceutical powder. The first part comprises Astragalus 7 RECEIVED TIME 4. N(I)Y 17:42 membranaceus, 130 g; Radix saposhnikoviae, 100 g; Herba ephedrae, 40 g; Flos Magnoliae, 60 g; Angelica dahurica, 60 g; Rhizoma Atractylodis Macrocephalae, 100 g; Poriacocos, 60 g; Bupleurum, 60 g; Radix Angelicae Sinensis, 60 g; Cortex Moutan Radicis, 60 g; Fructus Schisandrae Chinensis, 60 g; Fructus Mume, 60 g; Radix Scutellariae, 60 g; and Glycyrrhiza uralensis Fisch, 60 g. The second part comprises Astragalus membranaceus, 70 g; Radix saposhnikoviae, 50 g; Herba ephedrae, 20 g; Flos Magnoliae, 40 g; Angelica dahurica, 40 g; Rhizoma Atractylodis Macrocephalae, 50 g; Poriacocos, 40 g,; Bupleurum, 40 g; Radix Angelicae Sinensis, 40 g; Cortex Moutan Radicis, 40 g; Fructus Schisandrae Chinensis, 40 g; Fructus Mume, 40 g; Radix Scute/ariae, 40 g; and Glycyrrhiza uralensis Fisch, 40 g. [0034] a) breaking the Flos Magnoliae, Cortex Moutan Radicis, Radix saposhnikoviae, Radix Angelicae Sinensis, and Rhizoma Atractylodis Macrocephalae into pieces, adding water to the pieces, allowing to stand for 6 hours, filtering, extracting volatile oil, and collecting an aqueous filtrate and a herb residue; [0035] b) encaging the volatile oil by using -cyclodextrin to yield a clathrate compound, a ratio of the volatile oil to the P-cyclodextrin being 1 mL: 8 g; [0036] c) mixing the Poriacocos, Fructus Mume, Herba ephedrae, Radix Scutellariae, and Glycyrrhiza uralensis Fisch with the herb residue collected in step a), adding water to the herb residue to yield a mixture, decocting the mixture twice each for 1.5 hours, and combining the mixture with the aqueous filtrate obtained in step a) to yield a first concentrate, the first concentrate having a relative density of 1.20 at 50"C; [0037] d) purifying the Angelica dahurica, Fructus Schisandrae Chinensis, Astragalus membranaceus, and Bupleurum using a 70 % (v/v) alcohol 8 RECEIVED TIME 4. NOV. 17:42 solution three times each for 2 hours, combining the alcohol solution and removing alcohol to yield a second concentrate, mixing the first concentrate and the second concentrate and vacuum drying the mixed concentrate to at 500C yield a powder; [0038] e) adding the clathrate compound and the pharmaceutical powder to the powder obtained in step d), drying, polishing, and packaging the pharmaceutical formulation at less than 50 0 C to yield a tablet. Example 3 [0039]A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, 150 g; Radix saposhnikoviae, 100 g; Herba ephedrae, 40 g; Flos Magnoliae, 50 g; Angelica dahurica, 50 g; Rhizoma Atractylodis Macrocephalae, 100 g; Poriacocos, 50 g; Bupleurum, 50 g; Radix Angelicae Sinensis, 50 g; Cortex Moutan Radicis, 50 g; Fructus Schisandrae Chinensis, 50 g; Fructus Mume, 50 g; Radix Scutellariae, 50 g; and Glycyrrhiza uralensis Fisch, 50 g. [0040]A method for preparing the pharmaceutical formulation, comprises the following steps: [0041] a) breaking the Flos Magnoliae, Cortex Moutan Radicis, Radix saposhnikoviae, Radix Angelicae Sinensis, and Rhizoma Atractylodis Macrocephalae into pieces, adding water to the pieces, allowing to stand for 6 hours, filtering, extracting volatile oil, and collecting an aqueous filtrate and a herb residue; [0042] b) encaging the volatile oil by using P-cyclodextrin to yield a clathrate compound, a ratio of the volatile oil to the p-cyclodextrin being 1 mL: 8 g; 9 RECEIVED TIME 4, NOV. 17:42 [0043] c) mixing the Poriacocos, Fructus Mume, Herba ephedrae, Radix Scutellariae, and Glycyrrhiza uraiensis Fisch with the herb residue collected in step a), adding water to the herb residue to yield a mixture, decocting the mixture twice each for 1.5 hours, and combining the mixture with the aqueous filtrate obtained in step a) to yield a first concentrate, the first concentrate having a relative density of 1.20 at 50*C; [0044] d) purifying the Angelica dahurica, Fructus Schisandrae Chinensis, Astragalus membranaceus, and Bupleurum using a 70 % (v/v) alcohol solution three times each for 2 hours, combining the alcohol solution and removing alcohol to yield a second concentrate, mixing the first concentrate and the second concentrate and vacuum drying the mixed concentrate at 500C to yield a powder; [0045] e) adding the clathrate compound and a medical starch to the clear paste or the powder, drying, polishing, and packaging the pharmaceutical formulation at less than 500C to yield a concentrated granule. Example 4 [0046] A pharmaceutical formulation for treatment of allergic rhinitis, comprises the following ingredients with corresponding parts by weight: Astragalus membranaceus, 150 g; Radix saposhnikoviae, 100 g; Herba ephedrae, 40 g; Flos Magnoliae, 50 g; Angelica dahurica, 50 g; Rhizoma Atractylodis Macrocephalae, 100 g; Poriacocos, 50 g; Bupleurum, 50 g; Radix Angelicae Sinensis, 50 g; Cortex Moutan Radicis, 50 g; Fructus Schisandrae Chinensis, 50 g; Fructus Mume, 50 g; Radix Scutellariae, 50 g; and Glycyrrhiza uralensis Fisch, 50 g. [0047] A method for preparing the pharmaceutical formulation, comprises the 10 RECEIVED TIME 4. NOV. 17:42 following steps: 10048] a) breaking the Flos Magnoliae, Cortex Moutan Radicis, Radix saposhnikoviae, Radix Angelicae Sinensis, and Rhizoma Atractylodis Macrocephalae into pieces, adding water to the pieces, allowing to stand for 6 hours, filtering, extracting volatile oil, and collecting an aqueous filtrate and a herb residue; [0049] b) encaging the volatile oil by using P-cyclodextrin to yield a clathrate compound, a ratio of the volatile oil to the P-cyclodextrin being 1 mL: 8 g; [0050] c) mixing the Poriacocos, Fructus Mume, Herba ephedrae, Radix Scutellariae, and Glycyrrhiza uralensis Fisch with the herb residue collected in step a), adding water to the herb residue to yield a mixture, decocting the mixture twice each for 1.5 hours, and combining the mixture with the aqueous filtrate obtained in step a) to yield a first concentrate, the first concentrate having a relative density of 1.20 at 500C [0051] d) purifying the Angelica dahurica, Fructus Schisandrae Chinensis, Astragalus membranaceus, and Bupleurum using a 70 % (v/v) alcohol solution three times each for 2 hours, combining the alcohol solution and removing alcohol to yield a second concentrate, mixing the first concentrate and the second concentrate and vacuum drying the mixed concentrate at 50"C to yield a powder; [0052] e) adding the clathrate compound and microcrystalline cellulose to the clear paste or the powder, drying, polishing, and packaging the pharmaceutical formulation at less than 50*C to yield a capsule. [0053] Clinical experiments were conducted with regard to the pharmaceutical formulation from Oct., 2004 to Jul., 2005 in accordance with the random, control, 11 RECEIVED TIME 4. NOV. 17:42 and blind principles. 139 test samples were collected, 106 of which were randomly assigned to a first treatment group using the pharmaceutical formulation, and the other 33 samples were assigned to a second treatment group using rhinitis tablets for control. During the experiment, 3 samples lost the treatment records and 2 samples were out of contact, which were expelled from the experiment. Observations showed that 104 samples suffered from allergic rhinitis, among which, male were 56 in number, female 48, and the eldest were 55 years old, the youngest 18 years old, the longest disease duration were 15 years, the shortest 2 years. 19 samples suffered from seasonally intermittent allergic rhinitis, and 21 samples suffered from seasonally durative allergic rhinitis, among which, 18 samples suffered from mild allergic rhinitis, the other 22 suffered from heavy allergic rhinitis. 26 samples suffered from perennially intermittent allergic rhinitis, and 38 samples suffered from perennially durative allergic rhinitis, among which, 29 samples suffered from mild allergic rhinitis, the other 35 suffered from heavy allergic rhinitis. Besides, 98 samples suffered from rhinocnesmus, 101 suffered from sneezing, 103 suffered from nasal flow, 98 suffered from nasal obstruction, 19 suffered from concurrent chronic rhinitis, 14 suffered from concurrent chronic sinusitis, 2 suffered from concurrent asthma, 2 suffered from concurrent deflection of nasal septum, 1 suffered from concurrent atrophic rhinitis, and 1 suffered from concurrent nasal cyst. [0054] After ten days' observation, the total treatment efficiency in the treatment group using the pharmaceutical formulation reached 93.2%, and the effectual percentage was 85.4%. The effectual time was that: 18 cases took effect on the second day, 28 cases took effect on the third day, and 15 cases took effect on the fifth day. Totally, 61 cases took effect after five days' treatment. After ten days' treatment, 28 cases taking effect stopped administration, 69 cases continued administration. Within five months, 20 cases had no recurrence. In 2 cases of 12 RECEIVED TIME 4. NOV. 17:42 concurrent asthma, asthma syndrome was first relieved, and then allergic rhinitis disappeared. The treatment group using the rhinitis tablets had a total treatment efficiency of 83.9%, and the effectual percentage was 67.8%, which shows a huge difference with the experiment group. [0055] Safety analysis: No side effect has been reported. [0056] The clinical researches on the pharmaceutical formulation had been completed prior to Oct., 2006, and the results were sent to China Food and Drug Administration. The formulation was issued in 2009, with the batch number: 20091L01133. 13 RECEIVED TIME 4. NOV. 17:42